Effect of adding bezafibrate to standard lipid-lowering therapy on post-fat load lipid levels in patients with familial dysbetalipoproteinemia. A randomized placebo-controlled crossover trial

MLA

Charlotte Koopal, et al. “Effect of Adding Bezafibrate to Standard Lipid-Lowering Therapy on Post-Fat Load Lipid Levels in Patients with Familial Dysbetalipoproteinemia. A Randomized Placebo-Controlled Crossover Trial.” Journal of Lipid Research, vol. 58, no. 11, Nov. 2017, pp. 2180–87. EBSCOhost, https://doi.org/10.1194/jlr.M076901.

APA

Charlotte Koopal, A. David Marais, Jan Westerink, Yolanda van der Graaf, & Frank L.J. Visseren. (2017). Effect of adding bezafibrate to standard lipid-lowering therapy on post-fat load lipid levels in patients with familial dysbetalipoproteinemia. A randomized placebo-controlled crossover trial. Journal of Lipid Research, 58(11), 2180–2187. https://doi.org/10.1194/jlr.M076901

Chicago

Charlotte Koopal, A. David Marais, Jan Westerink, Yolanda van der Graaf, and Frank L.J. Visseren. 2017. “Effect of Adding Bezafibrate to Standard Lipid-Lowering Therapy on Post-Fat Load Lipid Levels in Patients with Familial Dysbetalipoproteinemia. A Randomized Placebo-Controlled Crossover Trial.” Journal of Lipid Research 58 (11): 2180–87. doi:10.1194/jlr.M076901.